Kisqali (Ribociclib Succinate) Patent Expiration, LOE Window & CMS Spending
Kisqali (Ribociclib Succinate) by Novartis: FDA Orange Book core substance LOE 2032-05-09 (last listed 2036-10-14), 0 AB generics, $1.00B 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N209092 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2032-05-09 |
| Last Listed Patent or Exclusivity Date | 2036-10-14 |
| Orange Book Patents (*PED Extensions) | 24 patents (12 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.00B |
| 2024 Medicare Part D Spend | $775.5M |
| 2024 Medicaid Spend | $224.6M |
| Reported Wholesale Price Change (CA SB 17) | 15 WAC filings (max 26.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.